Amgen Stock Slips After More Analyst Criticism On Weight-Loss Drug Data: Retail Eyes ‘Great Buying Opportunity’
An RBC Capital analyst noted that while MariTide’s efficacy aligns with the brokerage’s expectations, its tolerability and long-term dosing regimen leave room for improvement.
